Stock Scorecard
Stock Summary for Compass Therapeutics Inc (CMPX) - $3.08 as of 2/21/2025 3:12:17 PM EST
Total Score
8 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CMPX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CMPX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CMPX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CMPX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for CMPX (26 out of 100)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 3 |
Stock Price Trend (Max of 10) | 0 |
Book Value (Max of 10) | 2 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for CMPX
Financial Details for CMPX
Company Overview |
|
---|---|
Ticker | CMPX |
Company Name | Compass Therapeutics Inc |
Country | USA |
Description | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts. |
Sector Name | REAL ESTATE & CONSTRUCTION |
Industry Name | BLANK CHECKS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 3.08 |
Price 4 Years Ago | 3.17 |
Last Day Price Updated | 2/21/2025 3:12:17 PM EST |
Last Day Volume | 1,125,343 |
Average Daily Volume | 2,345,216 |
52-Week High | 4.08 |
52-Week Low | 0.77 |
Last Price to 52 Week Low | 300.00% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 61.41 |
Sector PE | 63.46 |
5-Year Average PE | -6.84 |
Free Cash Flow Ratio | 3.14 |
Industry Free Cash Flow Ratio | 151.90 |
Sector Free Cash Flow Ratio | 106.99 |
Current Ratio Most Recent Quarter | 31.84 |
Total Cash Per Share | 0.98 |
Book Value Per Share Most Recent Quarter | 1.01 |
Price to Book Ratio | 3.36 |
Industry Price to Book Ratio | 8.03 |
Sector Price to Book Ratio | 12.38 |
Price to Sales Ratio Twelve Trailing Months | 498.56 |
Industry Price to Sales Ratio Twelve Trailing Months | 0.69 |
Sector Price to Sales Ratio Twelve Trailing Months | 4.44 |
Analyst Buy Ratings | 5 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 137,589,000 |
Market Capitalization | 423,774,120 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -8.33% |
Reported EPS 12 Trailing Months | -0.35 |
Reported EPS Past Year | -0.26 |
Reported EPS Prior Year | -0.34 |
Net Income Twelve Trailing Months | -47,759,000 |
Net Income Past Year | -42,494,000 |
Net Income Prior Year | -39,225,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | -6,523.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 135,402,000 |
Total Cash Past Year | 156,255,000 |
Total Cash Prior Year | 152,461,000 |
Net Cash Position Most Recent Quarter | 135,402,000 |
Net Cash Position Past Year | 156,255,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 157,060,000 |
Total Stockholder Equity Prior Year | 148,538,000 |
Total Stockholder Equity Most Recent Quarter | 138,398,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -48,100,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.35 |
Free Cash Flow Past Year | -40,648,000 |
Free Cash Flow Prior Year | -34,337,000 |
Options |
|
Put/Call Ratio | 11.75 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.29 |
MACD Signal | 0.37 |
20-Day Bollinger Lower Band | 0.67 |
20-Day Bollinger Middle Band | 2.06 |
20-Day Bollinger Upper Band | 3.44 |
Beta | 0.98 |
RSI | 51.57 |
50-Day SMA | 1.69 |
150-Day SMA | 2.43 |
200-Day SMA | 2.73 |
System |
|
Modified | 2/21/2025 9:10:29 PM EST |